MHAT for Womens Health - Nadezhda OOD
About MHAT for Womens Health - Nadezhda OOD
- Top Sponsors
- Top Collaborators
- Trials By Phase
- Recruitment Status
- Top Conditions
- Intervention Types
- Top Intervention Names
- Trials By Gender
Lead Sponsor
# Trials
Hoffmann-La Roche
5
G1 Therapeutics, Inc.
3
Bayer
2
Incyte Corporation
2
Celcuity, Inc.
1
EMD Serono Research & Development Institute, Inc.
1
Mersana Therapeutics
1
Clinical Trials at MHAT for Womens Health - Nadezhda OOD
During the past decade, MHAT for Womens Health - Nadezhda OOD conducted 15 clinical trials. In the 10-year time frame, 15 clinical trials started and 4 clinical trials were completed, i.e. on
average, 26.7% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 3 clinical trials were completed. i.e. 100%
of trials that started reached the finish line.
Trials List
Trail ID
Brief Title
Start Date
Completion Date
Status
Enrollment
A Study of Taselisib + Fulvestrant Versus Placebo + Fulvestrant in Participants With Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression During or After Aromatase Inhibitor Therapy
2015-04-09
2021-06-29
Terminated
631
Safety and Efficacy of Bevacizumab in Combination With Carboplatin and Paclitaxel for Metastatic, Recurrent or Persistent Cervical Cancer
2015-07-28
2019-01-15
Completed
152
Avelumab in First-line NSCLC (JAVELIN Lung 100)
2015-10-29
2022-12-31
Active, not recruiting
1,214
A European Registry Study to Prospectively Observe Treatment Patterns and Outcomes in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Unresectable Locally Advanced (LA) or Metastatic Breast Cancer (mBC) (SAMANTHA)
2016-11-16
2024-12-18
Active, not recruiting
629
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)
2017-02-02
2020-02-28
Terminated
102
G1T38, a CDK 4/6 Inhibitor, in Combination With Fulvestrant in Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer
2017-01-01
2023-10-01
Active, not recruiting
102
A Phase 1 Study of INCMGA00012 in Patients With Advanced Solid Tumors
2016-11-15
2024-04-27
Active, not recruiting
325
First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b
2017-12-12
2024-12-31
Recruiting
444
Clinical Trials Sponsors and Collaborators
Out of the total clinical trials conducted in "MHAT for Womens Health - Nadezhda OOD" #1 sponsor was "Hoffmann-La Roche" with 5 trials, followed by "G1 Therapeutics, Inc." with 3 trials
sponsored, "Bayer" with 2 trials sponsored, "Incyte Corporation" with 2 trials sponsored and "Celcuity, Inc."
with 2 trials sponsored. Other sponsors include -3 different institutions and
companies that sponsored additional 7 trials in total.
In terms of collaborators to trials, out of the total clinical trials conducted in "MHAT for Womens Health - Nadezhda OOD"
#1 collaborator was "Foundation Medicine, Inc." with 1 trials as a collaborator, "Merck KGaA, Darmstadt, Germany" with 1 trials as a collaborator and "Zai Lab (Shanghai) Co., Ltd." with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were
collaborators in the rest 3 trials.
Clinical Trials Conditions at MHAT for Womens Health - Nadezhda OOD
According to Clinical.Site data, the most researched conditions in "MHAT for Womens Health - Nadezhda OOD" are
"Breast Cancer" (6 trials), "Breast Neoplasm" (3 trials), "Carcinoma, Ductal, Breast" (2 trials), "Triple-Negative Breast Cancer" (2 trials) and "Advanced Breast Cancer" (1 trials). Many other conditions were trialed in "MHAT for Womens Health - Nadezhda OOD" in a lesser frequency.
Clinical Trials Intervention Types at MHAT for Womens Health - Nadezhda OOD
Most popular intervention types in "MHAT for Womens Health - Nadezhda OOD" are "Drug" (14 trials). Other intervention types were less common.
The name of intervention was led by "Carboplatin" (5 trials), "Paclitaxel" (5 trials), "Placebo" (4 trials), "Cisplatin" (3 trials) and "Fulvestrant" (3 trials). Other intervention names were less common.
Clinical Trials Genders at MHAT for Womens Health - Nadezhda OOD
The vast majority of trials in "MHAT for Womens Health - Nadezhda OOD" are
10 trials for "All" genders and 5 trials for "Female" genders.
Clinical Trials Status at MHAT for Womens Health - Nadezhda OOD
Currently, there are NaN active trials in "MHAT for Womens Health - Nadezhda OOD".
undefined are not yet recruiting,
3 are recruiting,
6 are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were 4 completed trials in MHAT for Womens Health - Nadezhda OOD,
undefined suspended trials,
and 2 terminated clinical trials to date.
Out of the total trials that were conducted in MHAT for Womens Health - Nadezhda OOD, 4 "Phase 1"
clinical trials were conducted, 5 "Phase 2" clinical
trials and 7 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 0 trials, and there were
also 0 trials that are defined as “Not Applicable".